Clinical Trials Logo

Neoplasm Recurrence clinical trials

View clinical trials related to Neoplasm Recurrence.

Filter by:
  • None
  • Page 1

NCT ID: NCT06046131 Recruiting - Neoplasm Metastasis Clinical Trials

Clinical, Genetic and Environmental Determinants of Prostate Cancer Progression.

KP-CARAIBES
Start date: February 28, 2023
Phase: N/A
Study type: Interventional

The course and progression of prostate cancer is highly variable, depending on the individual characteristics, the aggressiveness of the disease at the time of diagnosis as well as the ethno-geographic origins of the individuals. The general objective of the project is to identify the clinical, genetic and environmental determinants (risk factors) of the evolution, progression and complications of the disease according to the treatment options. Identifying modifiable and non-modifiable prognostic determinants of disease progression is a major challenge. This knowledge will help guide treatment choices but also, especially in high-risk populations (high incidence of disease) to better tailor prevention policies and possibly screening .

NCT ID: NCT05037279 Not yet recruiting - Bladder Cancer Clinical Trials

Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)

EVER
Start date: January 1, 2023
Phase: Phase 3
Study type: Interventional

The aim of this study is to evaluate the effect of Verity-BCG in patients with intermediate and high-risk non-muscle-invasive bladder cancer (NMIBC) and to compare our findings to the standard of care BCG formulation, OncoTICE (BCG) in order to examine our hypothesis that Verity-BCG is at least non-inferior to OncoTICE in achieving 24-month Recurrence Free Survival in NMIBC patients who are at high risk of recurrence and have never been treated with intradermal or intravesical BCG before, with the exception of tuberculosis vaccination in childhood.

NCT ID: NCT04653818 Completed - Clinical trials for Hepatocellular Carcinoma

HCV Related Hepatocellular Carcinoma Recurrence After Directly Acting Antivirals: A Randomized Controlled Trial

RCT
Start date: October 5, 2020
Phase: Phase 4
Study type: Interventional

Data regarding hepatocellular carcinoma (HCC) recurrence after directly acting antivirals (DAAs) given for hepatitis C virus treatment are contradictory. Surprisingly, some studies reported that DAAs are accompanied with higher HCC recurrence. But, other studies showed no rise or even decrease in HCC recurrence. Most of these studies were retrospective and some were non-randomized prospective studies. Here investigators aim to perform a randomized controlled trial to study this issue.

NCT ID: NCT01696565 Completed - Neoplasm Metastasis Clinical Trials

PG2 Phase I/II Clinical Study Intravenously Administered in Patients With Advanced Malignancy

Start date: December 2001
Phase: Phase 1/Phase 2
Study type: Interventional

The objectives of this Phase I/II study are: 1. To find out the maximum tolerated dose (MTD) of PG2 in patients with advanced malignancy receiving chemotherapy and to define a "Study Dose" for Phase II. 2. To evaluate the hematopoietic and immunological responses after administering of PG2. Primarily to study the biological response of PG2, defined as WBC count in this study, and secondarily to study the immunological factors, IL-2, IL-6, TGF-beta, and G-CSF.